Morningside Ventures has led a nearly US$10 million series A funding round in TransThera Biosciences Co. Ltd, a Chinese biotech start-up specialized in developing novel new chemical entity drugs.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
